The usefulness of treatment strategies by antagonists of each EP receptor has been reported in various types of malignancies; for example, the EP1 and EP2 receptors for breast cancer46,47, EP3 receptor for oral cancer48, and EP4 receptor for lung cancer and breast cancer43,49,50. Here, PTGER1 is linked to lung cancer.